ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
68.55
-0.58 (-0.84%)
At close: Nov 20, 2026, 4:00 PM EST
68.90
+0.35 (0.51%)
After-hours: Nov 20, 2026, 7:39 PM EST
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, ANI Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $103.38. The average 1-year stock price forecast is 50.81% higher than the current stock price, while the lowest is $85 (+24.00%) and the highest is $121 (+76.51%).
Price Target: $103.38 (+50.81%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ANI Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $90 | Hold | Maintains | $90 | +31.29% | Nov 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $121 | Buy | Reiterates | $121 | +76.51% | Nov 6, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $119 → $121 | Buy | Reiterates | $119 → $121 | +76.51% | Nov 6, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $115 | Buy | Maintains | $115 | +67.76% | Oct 22, 2026 |
| Oppenheimer | Oppenheimer | Hold Initiates $85 | Hold | Initiates | $85 | +24.00% | Sep 23, 2026 |
Financial Forecast
Revenue This Year
1.10B
from 883.37M
Increased by 24.30%
Revenue Next Year
1.22B
from 1.10B
Increased by 10.96%
EPS This Year
9.51
from 7.89
Increased by 20.52%
EPS Next Year
10.20
from 9.51
Increased by 7.30%
EPS and Forward PE are based on non-GAAP adjusted numbers.